Safety and Effectiveness of Transcutaneous Electrical Nerve Stimulation (TENS)-Assisted Weight Loss and/or Appetite Suppression
Overview
- Phase
- Not Applicable
- Intervention
- Not specified
- Conditions
- Weight Loss
- Sponsor
- Elira Therapeutics, Inc.
- Enrollment
- 161
- Locations
- 1
- Primary Endpoint
- Number of Participants With Treatment Emergent Adverse Events
- Status
- Completed
- Last Updated
- 4 years ago
Overview
Brief Summary
The objectives of this study are to demonstrate safety and effectiveness of a wearable patch TENS system (Appendix 2) in driving weight loss and appetite suppression when coupled with an integrated weight loss reduction strategy. The study is designed to demonstrate that TENS stimulation sufficient to drive weight loss and appetite suppression is safe and tolerable when compared to standard of care, and that adverse events/adverse device effects are similar to other TENS device use cases.
Detailed Description
Randomized, adaptive parallel arm study. Subjects will be initially screened during a screening period (+/- 7 days). During this screening period, subjects will sign an Informed Consent Form (ICF), have their weight/height and blood pressure measured as part of a physical exam, take a pregnancy test (females of child bearing potential), get blood drawn for analysis (blood lipids, HbA1c), and complete the PHQ-9 and pre-study survey. At the end of the screening period, eligible subjects will be enrolled/randomized in the study and be randomized to either a treatment or control group. After enrolling, both control and treatment subjects will be instructed to follow a healthy diet and reduce calories as desired for the duration of the study and will receive training on the use of the electronic scale and completion of paper diaries. For the treatment group, subjects will be instructed on use of the Elira wearable patch system. Photographs will be taken at the enrollment visit. Following this, subjects will enter the Therapy Period for \~24-weeks. At the 12 week visit, subjects will be assessed for weight loss, blood pressure, blood lipids, HbA1c, patient preference questionnaire and their participation will continue through months 4-6 for the Safety phase of the Therapy Period. The Therapy Period will be considered complete (pending laboratory results, adverse events or serious adverse events). Patient (treatment) photographs will also be taken at the 12 week visit. The study utilizes an adaptive approach where cohorts of enrolled/randomized subjects (in groups of \~25 per arm) are assessed for dose response and progression to achievement of primary and secondary endpoints. Frequent interim endpoint assessment utilizing Markov-chain Monte Carlo (MCMC) methods coupled with Longitudinal analyses will be utilized to determine sample sizes for future cohorts (assessed primarily via Normal dynamic linear modeling \[NDLM\]). Long term safety of the device will be shown through 6 months of usage.
Investigators
Eligibility Criteria
Inclusion Criteria
- •Subject is between 18 - 65 years of age inclusive.
- •Subject has a BMI of 25-35 kg/ m2 inclusive.
- •Subject has signed the informed consent form and is able to comply with study protocol and adhere to study visit schedule.
- •Subject is able to wear and use a wearable, patch TENS system.
- •Subject is able to use a touch screen hand held smart phone.
- •Subject is fluent in English and can complete questionnaires.
- •Females of childbearing potential (FOCBP) must have a negative urine pregnancy test at screening or enrollment visit, prior to placement of ELIRA device.
- •Subject is male or non-pregnant, non-lactating female, who agrees to use effective contraceptive methods throughout the length of the trial based on PI approval.
Exclusion Criteria
- •Subject has any known gastrointestinal disorder that in the opinion of the PI precludes enrollment into the trial.
- •Subject has had a prior bariatric procedure or any previous procedure on the stomach.
- •Subject has any significant multisystem disease in the opinion of the PI.
- •Subject has \> 6.5 HbA1c.
- •Subject has significant cardiac arrhythmia, ectopy, or significant cardiovascular disease.
- •Subject has an existing implanted electrical stimulator (e.g., pacemaker, AICD).
- •Subject is a female of child-bearing potential who is pregnant or intends to become pregnant during the trial period.
- •Subject has current and/or a history of cancer within the past 5 years (not including basal cell carcinoma or cervical carcinoma in situ).
- •Subject has had a weight change of + 5% of his/her Total Body Weight in the 3 months prior to screening.
- •Subject has a moderate / severe psychiatric disorder.
Outcomes
Primary Outcomes
Number of Participants With Treatment Emergent Adverse Events
Time Frame: 12 weeks
Treatment Emergent Adverse Events \[Time Frame: 12 weeks\] Safety/Tolerability will be assessed by the non-inferiority of incidence of serious adverse events (SAEs), unanticipated serious adverse events (USAEs), device-related SAEs (DSAEs), and unanticipated device-related SAEs (UDAEs) that are associated with the TENS therapy throughout the stimulation and the follow-up period versus historical control (compared with other TENS systems).
Change in Appetite as Measured by a Visual Analogue Scale From Baseline
Time Frame: 3 months
Appetite Changes \[Time Frame: 12 weeks\] Percent change in appetite scores at the end of the trial compared to Baseline between Treatment and Control. Subjects are asked to score level of satisfaction, fullness, hunger and ability to eat on a Visual Analogue Scale of 1 to 100 before and after meals with lower scores indicating lower satisfaction, fullness, hunger or ability to eat, respectively. Scores are captured in a diary once a week with 8 time points. The weeks are captured as week 0 through week 12. The time points at each week include: * 30 minutes before breakfast * 30, 60, and 90 minutes after breakfast * Pre-lunch * Midafternoon * 30 minutes before dinner * Bedtime For each of the four appetite suppression variables (satisfaction, fullness, hunger and ability to eat), the 8 time points at week zero will be averaged for the baseline score (baseline), and the 8 time points at week 12 will be averaged for the 3-month score (3month).
Secondary Outcomes
- Change in Percent Total Body Weight Loss(3 months)
- Changes in BMI(3 months)